US Advisors to Decide on Unproven Peptide Drugs

Advisers to the Food and Drug Administration (FDA) are scheduled to convene on July 23-24, 2026, to deliberate on lifting restrictions for several research peptides. These substances, including BPC-157 and MOTs-C, are currently sold through a gray market with limited evidence supporting their safety and efficacy in humans. Their proponents, like retail pharmacist Mohammed Chammout, eagerly await a potential shift to a legal Category 1 status, which would allow US compounding pharmacies to produce and dispense them.

These peptides, distinct from approved medications like GLP-1 drugs, are often sourced from gray market compounding pharmacies, with many originating from China. They are promoted online for various wellness goals, such as weight loss and anti-aging. However, experts like Dr. Eric Topol and consumer advocates such as Public Citizen warn against their use due to significant safety concerns and a lack of rigorous clinical trials. The FDA's decision could legalize a market estimated to reach $2.2 billion annually.

The push for re-evaluation follows a 2023 ban on 19 research peptides by the Biden administration due to risks including priapism and tumor growth. Despite opposition from 90% of physicians surveyed, compounding pharmacies argue that easing restrictions would provide a safer supply than currently available. The financial implications are substantial, with Hims & Hers potentially capturing a significant share of this market after acquiring a US-based peptide facility in 2025.